Rituximab-Induced Interstitial Lung Disease in Pemphigus Patients: Two Case Reports and Review of the Literature


  • Niporn Jariyakulwong Department of dermatology, Phramongkutklao college of medicine, Thailand.
  • Julphat Intarasupht Department of dermatology, Phramongkutklao college of medicine, Thailand.


Rituximab, Drug-induced interstitial lung disease, Pemphigus


Rituximab is a CD20-directed cytolytic antibody approved as a novel effective first-line treatment for severe pemphigus vulgaris and pemphigus foliaceus. Rituximab is generally safe, but uncommon fatal adverse events such as drug-induced interstitial lung disease have been reported. We reported two patients who developed rituximab-induced interstitial lung disease despite receiving the recommended standard dosages and review of the literature.


Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers 2017 11;3:17026.

Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020;34:1900-13.

Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008;128:2850-8.

Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hügli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269-72.

Research C for DE and. Rituximab (marketed as Rituxan) Information. FDA [Internet]. 2022 Feb 24 [cited 2023 Sep 3]; Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/rituximab-marketed-rituxan-information

Theerasuk K, Yingluk W, Teeraya P, et al. Clinical and radiological correlation of pulmonary complications in CHOP versus rituximab-CHOP regimen treated non-Hodgkin’s lymphoma in Thailand 2017.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.

Douze M, Sabina V, Adrien J, et al. Rituximab Induced Interstitial Lung Disease Diagnosis, Treatment Outcome, and Risk’s Factor, a Place for Transbronchial Pulmonary Cryobiopsy. Case Reports in Clinical Medicine 2021;10:284-94.

Lioté H, Lioté F, Séroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: A systematic literature review. Eur Respir J 2010;35:681-7.

Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 2009;44:922-34.

Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012;51:653-62.

MASTER AM, LASSER RP, BECKMAN G. Tables of average weight and height of Americans aged 65 to 94 years: relationship of weight and height to survival. J Am Med Assoc 1960;172:658-62.

Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol 2015;95:928-32.




How to Cite

Jariyakulwong, N., & Intarasupht, J. (2024). Rituximab-Induced Interstitial Lung Disease in Pemphigus Patients: Two Case Reports and Review of the Literature. Thai Journal of Dermatology, 40(1), 18–22. Retrieved from https://he02.tci-thaijo.org/index.php/TJD/article/view/265873



Case Report